Ribociclib Plus Endocrine Therapy Shows Promise in Certain Breast Cancer Subtypes
Ribociclib shows Promise in Aggressive Breast Cancer Subtypes
New data from the RIGHT Choice study suggest ribociclib (Kisqali) combined with endocrine therapy may offer a progression-free survival (PFS) benefit for patients with luminal B and HER2-enriched subtypes of breast cancer.
These findings, presented at the 2024 San Antonio Breast Cancer Symposium, stem from a subgroup analysis of the phase 2 RIGHT Choice study (NCT03839823).While the initial study demonstrated a significant PFS benefit for ribociclib plus endocrine therapy compared to chemotherapy in patients with aggressive HR-positive, HER2-negative advanced breast cancer, this new analysis delves deeper into specific subtypes.
“Contrary results in the [chemotherapy] arm suggest that these signatures warrant further studies on their potential predictive value,” the study authors noted. “These data are hypothesis generating and should be interpreted with caution due to small sample sizes.”
The analysis focused on patients with luminal A, luminal B, HER2-enriched, and basal-like subtypes. Notably, in patients with luminal B breast cancer, the median PFS was 38.0 months with ribociclib plus endocrine therapy compared to 21.7 months with chemotherapy. similarly,in the HER2-enriched subtype,median PFS was 17.4 months with ribociclib versus 8.0 months with chemotherapy.
When combining luminal B and HER2-enriched subtypes, both associated with poorer prognoses, the median PFS was 38.0 months for those receiving ribociclib plus endocrine therapy compared to 18.4 months for those receiving chemotherapy.
Further analysis revealed that patients with high ESR1 expression,a gene linked to estrogen receptor activity,experienced longer median PFS (38.0 months) compared to those with low ESR1 expression (32.5 months) when treated with ribociclib.
These findings offer encouraging insights into the potential of ribociclib as a treatment option for specific subtypes of aggressive breast cancer. However, further research with larger sample sizes is needed to confirm these results and solidify the role of gene expression signatures in predicting treatment response.
Ribociclib Shows Promise in Aggressive Breast Cancer Subtypes: An Interview with Dr. [Specialist Name]
Dr.[Specialist Name],thank you for joining us today to discuss the exciting new findings regarding ribociclib’s potential in treating aggressive breast cancer subtypes.
Could you elaborate on the key takeaways from the RIGHT Choice study subgroup analysis presented at the 2024 san Antonio Breast Cancer Symposium?
The study suggested that ribociclib in combination with endocrine therapy demonstrated a significant progression-free survival (PFS) benefit compared to chemotherapy in patients with luminal B and HER2-enriched subtypes of breast cancer. Can you explain the significance of these findings, notably for these specific subtypes?
The analysis also highlighted the potential role of ESR1 gene expression as a predictor of treatment response.What are the implications of this finding for personalized medicine in breast cancer treatment?
While these results are encouraging, you mentioned the need for further research. What are some key areas that future studies should focus on?
what message would you like to convey to patients diagnosed with aggressive breast cancer subtypes based on these promising findings?